1. Tofacitinib significantly improves patient-reported outcomes compared to placebo in the management of juvenile idiopathic arthritis (JIA). Evidence Rating Level: ...
1. After a 24-week treatment period, a significantly greater proportion of patients randomized to momelotinib had symptom scores reduced by ...
1. Oral baricitinib is superior to placebo regarding hair regrowth at 36 weeks. 2. Oral baricitinib led to lower severity ...
1. Patients in the tofacitinib group reported significantly fewer flare-ups (29%) compared to placebo (53%) by week 44. 2. The ...
1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the ...
1. The proportion of patients with EASI ≥75% was significantly greater in the upadacitinib 30 mg and 15 mg groups ...
